Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
Copyright policy )Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen‐activated protein kinase kinase (MEK) inhibitors for patients with PCPs. With continued successful responses, it is proposed that BRAF (and MEK) inhibitors be evaluated for the neoadjuvant treatment of patients with PCPs.
- TU Dresden Germany
- Massachusetts General Hospital United States
- King's College Hospital NHS Foundation Trust United Kingdom
- Dresden University of Technology
- King's College Hospital United Kingdom
Male, Proto-Oncogene Proteins B-raf, Middle Aged, Craniopharyngioma, Young Adult, Antineoplastic Combined Chemotherapy Protocols, Mutation, Humans, Pituitary Neoplasms, Molecular Targeted Therapy, Protein Kinase Inhibitors, Aged
Male, Proto-Oncogene Proteins B-raf, Middle Aged, Craniopharyngioma, Young Adult, Antineoplastic Combined Chemotherapy Protocols, Mutation, Humans, Pituitary Neoplasms, Molecular Targeted Therapy, Protein Kinase Inhibitors, Aged
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).85 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!